Finally, through our other business development activities, we successfully outlicensed aminocandin and IP 751 and we have discussions ongoing for the outlicensing of pagoclone, all designed to further focus our efforts in urology and endocrinologyCompare his statement in last year's report:
We are also optimistic about the positive results of our pagoclone Phase II study in stuttering and the upcoming initiation of our Phase III clinical program.Unfortunately, my instincts tell me that the "on-going discussion" is a way of spinning bad news. Instead of saying "we are not going forward with Pagoclone and this is our third aborted attempt to find a disorder for Pagoclone", they say "we are in on-going discussion for outlicensing of Pagoclone. We are doing good because we make money by out-licensing". You can always say that you have on-going discussions, and of course they are secret so you can't reveal any details.
There was an analyst conference call today. Surely, some analyst is going to ask the question. If they are any good... If anyone has the link or transcript, please let us know.